Evaluation of antioxidant systems (coenzyme Q10 and total antioxidant capacity) in morbid obesity before and after biliopancreatic diversion.
Biliopancreatic diversion (BPD) is a surgical procedure performed in patients with untreatable obesity and insulin resistance. The demonstrated metabolic and hormonal results of this procedure include the reversal of insulin resistance; an increase in diet-induced thermogenesis; and modifications of gut hormones, such as gastrin, enteroglucagon, neurotensin, and cholecystokinin. On the other hand, obesity is a condition of increased oxidative stress; however, few studies have investigated antioxidant systems in obese persons with BPD. To evaluate the metabolic status and antioxidant systems in such patients, we studied a group of 11 morbidly obese patients, aged 28 to 62 years, with a mean body mass index (BMI) of 54.71 +/- 2.52 kg/m(2), before and after successful BPD (mean post-BPD BMI, 44.68 +/- 1.51 kg/m(2)). A control group composed of 10 slightly overweight women, with a mean BMI of 28.5 +/- 0.72 kg/m(2), was also studied. Coenzyme Q(10) (CoQ(10)) levels (also normalized for cholesterol levels) and total antioxidant capacity in blood plasma were assessed in these populations. The most striking datum was the extremely low level of CoQ(10) in postoperative period (0.34 +/- 0.16 vs 0.66 +/- 0.09 mug/mL, P = .04); also, the data corrected for cholesterol levels presented the same pattern, with a more marked significance (152.46 +/- 11.13 vs 186.4 +/- 17.98 nmol/mmol, P = .001). This could be due to lipid malabsorption after surgery. In fact, the pre-BPD data present all the metabolic and hormonal characteristics of severe obesity; and after BPD, there was a net improvement in the metabolic parameters. The first pathophysiologic phenomenon seems to be lipid malabsorption that has been argued to be the cause of insulin resistance reversion. This metabolic interpretation is also confirmed by the absence of significant variations of total antioxidant capacity (57.5 +/- 5.3 vs 66 +/- 5.3). The mechanisms of these phenomena remain to be established. These data suggest the importance of correcting postsurgical metabolic complications, in these clinical populations, with CoQ(10) supplementation.
Mancini
Antonio
A
Endocrinology, Catholic University of the Sacred Heart, 00135 Rome, Italy. mancini.giac@mclink.it
Leone
Erika
E
Festa
Roberto
R
Grande
Giuseppe
G
Di Donna
Vincenzo
V
De Marinis
Laura
L
Pontecorvi
Alfredo
A
Tacchino
Roberto Maria
RM
Littarru
Gian Paolo
GP
Silvestrini
Andrea
A
Meucci
Elisabetta
E
D000328:Adult; D000975:Antioxidants / Q000378:metabolism*; D052160:Benzothiazoles; D015904:Biliopancreatic Diversion; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009767:Obesity, Morbid / Q000097:blood* / Q000601:surgery*; D018709:Statistics, Nonparametric; D013451:Sulfonic Acids / Q000032:analysis; D013844:Thiazoles / Q000032:analysis; D014280:Triglycerides / Q000097:blood; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000097:blood; D014527:Uric Acid / Q000097:blood
D000975:Antioxidants; D052160:Benzothiazoles; D001786:Blood Glucose; D007328:Insulin; D013451:Sulfonic Acids; D013844:Thiazoles; D014280:Triglycerides; D014451:Ubiquinone; D014527:Uric Acid; C002502:2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid; D002784:Cholesterol; C024989:coenzyme Q10